作者
Xu Wang, Ke Feng Li, Erwin Adams, Ann Van Schepdael
发表日期
2011/5/1
来源
Current drug metabolism
卷号
12
期号
4
页码范围
395-410
出版商
Bentham Science Publishers
简介
Enzymes are major drug targets in drug discovery and development processes in the pharmaceutical and biotechnology industry. A recent survey found that nearly half of all the marketed small-molecule drugs are inhibitors of enzymes. Matrix metalloproteinases (MMPs) are a family of 28 enzymes capable of degrading the constituents of the extracellular matrix (ECM) and the basementmembrane. MMPs play an essential role in several normal physiological processes including growth, wound healing and tissue repair. Over-expression and activation of MMPs has been linked to a range of diseases which include osteoarthritis, tumor metastasis, angiogenesis and cardiovascular diseases. The development of MMP inhibitors as therapeutic agents has kept an important place in drug discovery. Therefore, there is also an increasing need for robust analytical methods for evaluation of inhibitory potency and for the …
引用总数
2011201220132014201520162017201820192020202121357351211
学术搜索中的文章